TY - JOUR
T1 - Digitally-enabled, person-centred care (PCC) in allergen immunotherapy
T2 - An ARIA-EAACI Position Paper
AU - Pfaar, Oliver
AU - Sousa-Pinto, Bernardo
AU - Papadopoulos, Nikolaos G.
AU - Larenas-Linnemann, Désirée E.
AU - Ordak, Michal
AU - Torres, Maria J.
AU - Mösges, Ralph
AU - Klimek, Ludger
AU - Zuberbier, Torsten
AU - Matricardi, Paolo M.
AU - Berger, Uwe E.
AU - Berger, Markus
AU - Dramburg, Stephanie
AU - Mahler, Vera
AU - Toppila-Salmi, Sanna K.
AU - Bergmann, Karl Christian
AU - Ollert, Markus
AU - Tripodi, Salvatore
AU - Jutel, Marek
AU - Agache, Ioana
AU - Eguiluz-Gracia, Ibon
AU - Canonica, G. Walter
AU - Akdis, Cezmi A.
AU - Sokolowska, Milena
AU - Sofiev, Mikhail
AU - Shamji, Mohamed H.
AU - Czarlewski, Wienczyslawa
AU - Fonseca, Joao A.
AU - Bedbrook, Anna
AU - Bousquet, Jean
N1 - Publisher Copyright:
© 2024 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2024/8
Y1 - 2024/8
N2 - In rhinitis and asthma, several mHealth apps have been developed but only a few have been validated. However, these apps have a high potential for improving person-centred care (PCC), especially in allergen immunotherapy (AIT). They can provide support in AIT initiation by selecting the appropriate patient and allergen shared decision-making. They can also help in (i) the evaluation of (early) efficacy, (ii) early and late stopping rules and (iii) the evaluation of (carried-over) efficacy after cessation of the treatment course. Future perspectives have been formulated in the first report of a joint task force (TF)—Allergic Rhinitis and Its Impact on Asthma (ARIA) and the European Academy of Allergy and Clinical Immunology (EAACI)—on digital biomarkers. The TF on AIT now aims to (i) outline the potential of the clinical applications of mHealth solutions, (ii) express their current limitations, (iii) make proposals regarding further developments for both clinical practice and scientific purpose and (iv) suggest which of the tools might best comply with the purpose of digitally-enabled PCC in AIT.
AB - In rhinitis and asthma, several mHealth apps have been developed but only a few have been validated. However, these apps have a high potential for improving person-centred care (PCC), especially in allergen immunotherapy (AIT). They can provide support in AIT initiation by selecting the appropriate patient and allergen shared decision-making. They can also help in (i) the evaluation of (early) efficacy, (ii) early and late stopping rules and (iii) the evaluation of (carried-over) efficacy after cessation of the treatment course. Future perspectives have been formulated in the first report of a joint task force (TF)—Allergic Rhinitis and Its Impact on Asthma (ARIA) and the European Academy of Allergy and Clinical Immunology (EAACI)—on digital biomarkers. The TF on AIT now aims to (i) outline the potential of the clinical applications of mHealth solutions, (ii) express their current limitations, (iii) make proposals regarding further developments for both clinical practice and scientific purpose and (iv) suggest which of the tools might best comply with the purpose of digitally-enabled PCC in AIT.
KW - allergen immunotherapy
KW - allergy
KW - AllergyMonitor®
KW - digital biomarkers
KW - MASK-air®
UR - http://www.scopus.com/inward/record.url?scp=85192175077&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38700063
U2 - 10.1111/all.16135
DO - 10.1111/all.16135
M3 - Article
C2 - 38700063
AN - SCOPUS:85192175077
SN - 0105-4538
VL - 79
SP - 2037
EP - 2050
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 8
ER -